U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951749) titled 'Evaluating Efficacy and Safety of Berotralstat in Preventing Angioedema Attacks in Subjects With Acquired Angioedema Due to C1 Inhibitor Deficiency (AAE)' on Oct. 19.

Brief Summary: The primary aim of the study is to explore the effectiveness of Berotralstat in preventing angioedema attacks in patients with Acquired Angioedema (AAE-C1-INH).

Study Start Date: Nov. 15

Study Type: INTERVENTIONAL

Condition: Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)

Intervention: DRUG: Berotralstat

Patients will receive capsules of oral Berotralstat for 24 weeks until the end of the study.

Recruitment Status: NOT_YET_RECRUIT...